SEN177

Overview

SEN177 is an orally effect glutamine cyclase ( QC ) inhibitor. The K i of SEN177 for human glutamine cyclase ( hQC ) is 20 nM, and the IC 50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Amyloid-β | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > CD47 | Products > Signaling Pathways > Huntingtin

Product Information

• Catalog No.: HY-136780
• CAS No.: 2117405-13-5
• Molecular Formula: C18H19FN6
• Molecular Weight: 338.38
• Purity: 98.76%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source